Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin

Chuanwen Lu, Changxia Shao, Everardo Cobos, Kamaleshwar P. Singh, Weimin Gao

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The development of novel targeted therapies has become an important research focus for lung cancer treatment. Our previous study has shown leptomycin B (LMB) significantly inhibited proliferation of lung cancer cells; however, p53 wild type lung cancer cells were resistant to LMB. Therefore, the objective of this study wtreatment with LMB to A549 cells significantly decreased the 50% inhibitory concentration (IC50) as compared to that of LMB alone (4.4 nM vs. 10.6 nM, P<0.05). Analysis of cell cycle and apoptosis by flow cytometry further confirmed the cytotoxic data. To investigate molecular mechanisms for this drug combination effects, p53 pathways were analyzed by Western blot, and nuclear proteome was evaluated by two dimensional-difference gel electrophoresis (2D-DIGE) and mass spectrometry. In comparison with control groups, the levels of p53, phospho-p53 (ser15), and p21 proteins were significantly increased while phospho-p53 (Thr55) and survivin were significantly decreased after treatments of pre-DOX and LMB (P<0.05). The 2D-DIGE/MS analysis identified that sequestosome 1 (SQSTM1/p62) had a significant increase in pre-DOX and LMB-treated cells (P<0.05). In conclusion, our results suggest that drug-resistant lung cancer cells with p53 wild type could be sensitized to cell death by scheduled combination treatment of DOX and LMB through activating and restoring p53 as well as potentially other signaling pathway(s) involving sequestosome 1.

Original languageEnglish
Article numbere32895
JournalPloS one
Issue number3
StatePublished - Mar 7 2012


Dive into the research topics of 'Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin'. Together they form a unique fingerprint.

Cite this